Table 1.
Preclinical pharmacological cardioprotective therapies tested in animal models of pulmonary hypertension (PH)
| Pharmacological cardioprotective approach | Model of PH used to test the therapy | References | Disease category/subtype of PH targeted |
|---|---|---|---|
| ‐ Interference with the epigenetic control of cardiac gene transcription | ‐ Pulmonary artery banding | (Cho et al., 2010; Bogaard et al., 2011) | Groups 1 and 3 |
| ‐ Monocrotaline model | |||
| ‐ Interference with miRNAs | ‐ Chronic hypoxia model | (Pullamsetti et al., 2012; Brock et al., 2014) | Group 3 |
| ‐ Interference with nuclear factor κ‐B‐mediated modulation of Notch signalling | ‐ Monocrotaline model | (Kumar et al., 2012) | Group 1 |
| ‐ Interference with cardiomyocyte energy metabolism | ‐ Pulmonary artery banding | (Piao et al., 2010) | Group 1 |
| ‐ Monocrotaline model | (Piao et al., 2010) | – | |
| ‐ Interference with mitochondrial dynamics | ‐ Monocrotaline model | (Marsboom et al., 2012; Ryan et al., 2013) | Groups 1 and 3 |
| ‐ Chronic hypoxia model | |||
| ‐ Inhibition of the sodium‐hydrogen‐exchanger‐1 | ‐ Monocrotaline model | (Chen et al., 2001) | Group 1 |
| ‐ Inhibition of apoptosis and antioxidant therapy | ‐ Not tested in PH | – | – |
In the above table, the animal models of PH are categorized according to the group of PH they represent. Group‐1, pulmonary arterial hypertension and group‐3: PH associated with lung disease (Maarman et al., 2013).